Description

SUSTEN 100 MG INJ 1ML

Indications

SUSTEN 100 MG INJ 1ML is primarily indicated for the management of conditions related to progesterone deficiency. It is commonly used in hormone replacement therapy, particularly for women undergoing assisted reproductive technology (ART) such as in vitro fertilization (IVF). Additionally, SUSTEN may be prescribed for the treatment of menstrual disorders and to support the luteal phase in women with inadequate luteal function. Its role in preventing preterm labor in certain high-risk pregnancies is also noteworthy.

Mechanism of Action

The active ingredient in SUSTEN is micronized progesterone, which is a naturally occurring steroid hormone. Progesterone plays a crucial role in the menstrual cycle and in maintaining the early stages of pregnancy. It works by binding to progesterone receptors in target tissues, leading to a cascade of biological effects. These effects include the preparation of the endometrium for implantation of the fertilized egg, suppression of ovulation, and modulation of immune responses to support pregnancy. By mimicking the natural hormone, SUSTEN helps to stabilize the uterine lining and reduce the risk of miscarriage in women with low progesterone levels.

Pharmacological Properties

SUSTEN is characterized by its pharmacokinetic properties, which include rapid absorption and a relatively short half-life. After intramuscular injection, SUSTEN is quickly distributed throughout the body, with peak plasma concentrations typically reached within a few hours. The drug is metabolized primarily in the liver, and its metabolites are excreted via urine. The formulation of SUSTEN as a micronized preparation enhances its bioavailability compared to non-micronized progesterone, allowing for effective therapeutic outcomes at lower doses.

Contraindications

SUSTEN should not be used in individuals with a known hypersensitivity to progesterone or any of the excipients in the formulation. It is contraindicated in patients with a history of thromboembolic disorders, such as deep vein thrombosis or pulmonary embolism, as progesterone can potentially exacerbate these conditions. Additionally, it should not be administered in cases of undiagnosed vaginal bleeding, liver disease, or certain types of cancers, including breast cancer, where hormone therapy may be inappropriate.

Side Effects

While SUSTEN is generally well-tolerated, some patients may experience side effects. Common side effects include headache, breast tenderness, fatigue, and mood changes. In some cases, patients may report gastrointestinal disturbances such as nausea or abdominal discomfort. Rare but serious side effects can include allergic reactions, severe liver dysfunction, and thromboembolic events. Patients should be advised to report any unusual or severe symptoms to their healthcare provider promptly.

Dosage and Administration

The recommended dosage of SUSTEN 100 MG INJ 1ML varies based on the indication and the individual patient’s needs. For luteal phase support in ART, a typical regimen may involve administering one injection of 100 mg intramuscularly daily, starting from the day of embryo transfer until the end of the first trimester. For other indications, the dosage may differ, and it is essential for healthcare providers to tailor the treatment plan according to the patient’s specific circumstances. SUSTEN is intended for intramuscular use only and should be administered by a qualified healthcare professional to ensure proper technique and minimize discomfort.

Interactions

SUSTEN may interact with other medications, which can influence its efficacy and safety. Co-administration with certain anticoagulants may increase the risk of bleeding, while drugs that induce liver enzymes, such as rifampicin or phenobarbital, may reduce the effectiveness of SUSTEN by increasing its metabolism. It is crucial for healthcare providers to review all medications the patient is taking, including over-the-counter drugs and herbal supplements, to avoid potential interactions. Patients should be counseled on the importance of disclosing their complete medication history.

Precautions

Before initiating treatment with SUSTEN, healthcare providers should conduct a thorough medical history and physical examination. Special caution is warranted in patients with a history of cardiovascular disease, hypertension, diabetes, or migraines, as these conditions may be exacerbated by hormone therapy. Regular monitoring of liver function and blood pressure is recommended during treatment. Additionally, patients should be informed about the signs and symptoms of potential complications, such as thrombosis or liver dysfunction, and advised to seek medical attention if they experience any concerning symptoms.

Clinical Studies

Clinical studies have demonstrated the efficacy of SUSTEN in improving pregnancy outcomes in women undergoing ART. In randomized controlled trials, the use of micronized progesterone has been associated with higher rates of clinical pregnancy and live births compared to placebo. Furthermore, studies have shown that SUSTEN effectively supports the luteal phase in women with luteal phase defects, contributing to improved menstrual cycle regularity and reproductive health. Ongoing research continues to explore the broader applications of progesterone therapy in various gynecological and obstetric conditions.

Conclusion

SUSTEN 100 MG INJ 1ML is a valuable therapeutic option for managing progesterone deficiency and supporting reproductive health. Its well-established mechanism of action, combined with favorable pharmacological properties, makes it an effective choice in various clinical scenarios, particularly in assisted reproductive technologies. However, careful consideration of contraindications, potential side effects, and drug interactions is essential for safe and effective use. As with any medication, ongoing communication between patients and healthcare providers is crucial to optimize treatment outcomes and ensure patient safety.